School of Chemistry, University of New South Wales (UNSW), Sydney 2052, Australia.
School of Optometry and Vision Science, University of New South Wales (UNSW), Sydney 2052, Australia.
Curr Med Chem. 2022;30(1):104-125. doi: 10.2174/0929867329666220613105424.
Antibiotic resistance is a growing global health problem when the discovery and development of novel antibiotics are diminishing. Various strategies have been proposed to address the problem of growing antibacterial resistance. One such strategy is the development of hybrid antibiotics. These therapeutic systems have been designed for two or more pharmacophores of known antimicrobial agents. This review highlights the latest development of antibiotic hybrids comprising two antibiotics (cleavable and non-cleavable) and combinations of biocidal and novel compounds to treat bacterial infections. The approach of dual-acting hybrid compounds has a promising future in overcoming drug resistance in bacterial pathogens.
当新型抗生素的发现和开发逐渐减少时，抗生素耐药性成为了一个日益严重的全球健康问题。为了解决抗菌药物耐药性日益增长的问题，人们提出了各种策略。其中一种策略是开发混合抗生素。这些治疗系统是为了将两种或更多种已知抗菌药物的药效团组合在一起而设计的。本综述重点介绍了由两种抗生素（可裂解和不可裂解）组成的抗生素混合药物以及杀菌化合物和新型化合物组合治疗细菌感染的最新进展。双效混合化合物的方法在克服细菌病原体的耐药性方面具有广阔的前景。
